OPHELIA (OPHELIA (OlaParib and durvalumab in HEad and neck squamous celL carcInomA) trial is
a Greek, investigator-initiated, randomized open-label window-of-opportunity phase II study.
Patients with operable histologically documented squamous-cell carcinoma of the oral cavity,
oropharynx, hypopharynx or larynx will be randomized between combination with durvalumab and
olaparib, cisplatin and olaparib, monotherapy with olaparib or no treatment, before starting